Characterization of intramuscular Isoflupredone acetate in horses: pharmacokinetics and effects on anti-inflammatory mediators and plasma electrolytes.
Authors: Sullivan Juliana, Blea Jeff, Morales Camilo J, McKemie Daniel S, Kass Philip H, Knych Heather K
Journal: BMC veterinary research
Summary
# Editorial Summary: Intramuscular Isoflupredone in Horses Isoflupredone acetate is routinely administered to performance horses for managing inflammatory conditions arising from training and musculoskeletal injury, yet its pharmacokinetics and systemic anti-inflammatory effects following intramuscular injection have remained poorly characterised, despite widespread clinical use via this route. Sullivan and colleagues administered a single 20 mg intramuscular dose of isoflupredone acetate to twelve horses, collecting blood and urine samples from 5 minutes through 312 hours post-injection and employing liquid chromatography-tandem mass spectrometry to quantify drug concentrations and characterise absorption, distribution, metabolism and elimination profiles. The study assessed pharmacodynamic effects by measuring suppression of endogenous cortisol and monitoring inflammatory biomarkers using an ex vivo inflammation model, providing direct evidence of the drug's systemic anti-inflammatory capacity. These findings establish critical baseline data on intramuscular isoflupredone acetate's behaviour within equine systems, including duration of action and effects on plasma electrolytes, bridging a significant gap between established intra-articular administration protocols and the practical demands of treating systemic and generalised inflammatory conditions in sport horses. Practitioners can now reference evidence-based pharmacokinetic parameters when timing repeat administrations and predicting therapeutic windows, whilst the anti-inflammatory biomarker data clarifies the systemic immunological effects beyond simple cortisol suppression.
Read the full abstract on PubMed
Practical Takeaways
- •Intramuscular isoflupredone provides a systemic anti-inflammatory effect in horses and may offer an alternative to intra-articular administration for diffuse inflammatory conditions associated with training and injury
- •Practitioners should monitor for HPA axis suppression with repeated dosing, as cortisol suppression was documented; single doses appear safe regarding electrolyte balance
- •This IM formulation could be useful for performance horses with widespread inflammation where joint-specific treatment is not indicated
Key Findings
- •Isoflupredone acetate 20 mg IM achieves measurable systemic concentrations in horses with pharmacokinetic parameters suitable for anti-inflammatory therapy
- •IM isoflupredone suppresses endogenous cortisol concentrations, indicating HPA axis suppression
- •The drug demonstrates dose-dependent anti-inflammatory effects on inflammatory biomarkers in ex vivo inflammation models
- •Plasma electrolytes remained stable following IM administration, with no clinically significant disturbances observed